DEVELOPMENT OF ALTERNATIVE AFFINITY CAPTURE REAGENTS

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: N43CO201000073
Agency Tracking Number: N43CO201000073
Amount: $149,800.00
Phase: Phase I
Program: SBIR
Awards Year: 2010
Solicitation Year: 2010
Solicitation Topic Code: NCI
Solicitation Number: PHS2010-1
Small Business Information
BIOTEX, INC.
8058 EL RIO ST, HOUSTON, TX, 77054-4104
DUNS: 969792050
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 George W. Jackson
 (713) 741-0111
 ashok@biotexmedical.com
Business Contact
Phone: (713) 741-0111
Email: ashok@biotexmedical.com
Research Institution
N/A
Abstract
Thousands of antibodies are produced every year by commercial companies. However, many of these antibodies are known to be poorly characterized and suboptimal across multiple applications. Polyclonal antibodies lack the reproducibility of monoclonal antibodies. Likewise, the production of monoclonal antibodies is expensive and may take months to produce. Even after production, a monoclonal antibody may not be specific for the target of interest, may not work in the needed assay, or could not be used in the needed assay, or could not be used in combination with other antibodies due to an antibody's large size and subsequent competition for overlapping binding domains. As such, the high costs associated with producing even small quantities of monoclonal antibodies represent a large barrier towards cost-effective reagents and resources for proteomic technology research and clinical adaptation. This project utilizes a new tool, "massively parallel selection of DNA aptamers" to rapidly identify high-affinity ligands to hundreds or even thousands of protein targets simultaneously. In this Phase I project, we will demonstrate the utility of our tool for selecting aptamers to 100 important cancer biomarkers and characterize many of them by accepted practices. The developed reagents will have tremendous value to the research community and potential to alleviate human suffering due to cancer.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government